抄録
Key Points: • Genetic alterations in immune checkpoint–related genes are frequent in IVLBCL. • Plasma cfDNA is an alternative tumor DNA source of IVLBCL to detect genetic alterations by comprehensive analyses.
| 本文言語 | English |
|---|---|
| ページ（範囲） | 1491-1502 |
| ページ数 | 12 |
| ジャーナル | Blood |
| 巻 | 137 |
| 号 | 11 |
| DOI | |
| 出版ステータス | Published - 2021 3月 18 |
| 外部発表 | はい |
ASJC Scopus subject areas
- 生化学
- 免疫学
- 血液学
- 細胞生物学
フィンガープリント
「Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood, Vol. 137, No. 11, 18.03.2021, p. 1491-1502.
研究成果: Article › 査読
}
TY - JOUR
T1 - Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma
AU - Shimada, Kazuyuki
AU - Yoshida, Kenichi
AU - Suzuki, Yasuhiro
AU - Iriyama, Chisako
AU - Inoue, Yoshikage
AU - Sanada, Masashi
AU - Kataoka, Keisuke
AU - Yuge, Masaaki
AU - Takagi, Yusuke
AU - Kusumoto, Shigeru
AU - Masaki, Yasufumi
AU - Ito, Takahiko
AU - Inagaki, Yuichiro
AU - Okamoto, Akinao
AU - Kuwatsuka, Yachiyo
AU - Nakatochi, Masahiro
AU - Shimada, Satoko
AU - Miyoshi, Hiroaki
AU - Shiraishi, Yuichi
AU - Chiba, Kenichi
AU - Tanaka, Hiroko
AU - Miyano, Satoru
AU - Shiozawa, Yusuke
AU - Nannya, Yasuhito
AU - Okabe, Asako
AU - Kohno, Kei
AU - Atsuta, Yoshiko
AU - Ohshima, Koichi
AU - Nakamura, Shigeo
AU - Ogawa, Seishi
AU - Tomita, Akihiro
AU - Kiyoi, Hitoshi
N1 - Funding Information: Conflict-of-interest disclosure: K.S. received research funding from Celgene, Otsuka Pharmaceutical, Merck Sharp & Dohme (MSD), Chugai Pharmaceutical, Kyowa Kirin (KK), and Daiichi Sankyo, and personal fees from AstraZeneca, Eizai, Celgene, Takeda Pharmaceutical, Janssen Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, Kyowa Kirin, Nippon Shinyaku, and Daiichi Sankyo. K. Kataoka received research funding from Otsuka Pharmaceutical, Chugai Pharmaceutical, Takeda Pharmaceutical, and Bristol Myers Squibb; has ownership in Asahi Genomics; and has received honoraria from Celgene, Eisai, Astellas Pharma, Novartis, Chugai Pharmaceutical, AstraZeneca, Sumitomo Dainippon Pharma, Kyowa Kirin, Janssen Pharmaceutical, and MSD. S.K. received research funding from Chugai Pharmaceutical and Kyowa Kirin, and received honoraria from Chugai Pharmaceutical and Kyowa Kirin. Y. Inoue received lecture fees from Celgene Corporation, Takeda Pharmaceutical, Mundipharma KK, Bristol Myers Squibb, Eisai, Novartis Pharma KK, Kyowa Kirin, and Sumitomo Dainippon Pharma. M.N. received research funding from Boehringer Ingelheim. S.O. provided consultancy services to Chordia Therapeutics and KAN Research Institute; has ownership in Chordia Therapeutics, Asahi Genomics, and Rebirthel; received research funding from KAN Research Institute, Chordia Therapeutics, Sumitomo Dainippon Pharma, Otsuka Pharmaceutical, and Eisai; and served on advisory committees for Chordia Therapeutics and Asahi Genomics. A.T. received research funding from Chugai Pharmaceutical, Astellas Pharma, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Shionogi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Teijin, Nippon Shinyaku, Nihon Pharmaceutical, Pfizer Japan, Mochida Pharmaceutical, Yakult Honsha, and Perseus Proteomics, and lecture fees from Chugai Pharmaceutical, Kyowa Kirin, Eisai, Takeda Pharmaceutical, Astellas Pharma, Nippon Shinyaku, Janssen Pharmaceutical, Zenyaku Kogyo, AbbVie GK, Bristol Myers Squibb, and SymBio Pharmaceutical. H.K. received research funding from Chugai Pharmaceutical, Kyowa Kirin, Zenyaku Kogyo, FUJIFILM Corporation, Daiichi Sankyo, Astellas Pharma, Otsuka Pharmaceutical, Nippon Shinyaku, Eisai, Pfizer Japan, Takeda Pharmaceutical, Novartis Pharma KK, Sumitomo Dainippon Pharma, Sanofi KK, Perseus Proteomics, and Celgene Corporation; consulting fees from Astellas Pharma, Amgen Astellas BioPharma KK, and Daiichi Sankyo; and honoraria from Bristol Myers Squibb, Astellas Pharma, and Novartis Pharma KK. Y.A. received lecture fees from Astellas Pharma, Mochida Pharmaceutical, Meiji Seika Pharma, Chugai Pharmaceutical, Kyowa Kirin, and Janssen Pharmaceutical. The remaining authors declare no competing financial interests. Funding Information: This work was supported, in part, by Grants-in-Aid from the Program to Disseminate Tenure Tracking System; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Young Scientists (B; 26860724 [K.S.]); MEXT, Japan (15K09473 [A.T.], 15H05912 [S.M.]); the National Cancer Center Research and Development Fund (26-A-4 [A.T.]); the Japan Agency for Medical Research and Development (AMED) (JP19cm0106501 [S.O.]); and JSPS (JP15H05909 [S.O.]). Publisher Copyright: © 2021 American Society of Hematology
PY - 2021/3/18
Y1 - 2021/3/18
N2 - Key Points: • Genetic alterations in immune checkpoint–related genes are frequent in IVLBCL. • Plasma cfDNA is an alternative tumor DNA source of IVLBCL to detect genetic alterations by comprehensive analyses.
AB - Key Points: • Genetic alterations in immune checkpoint–related genes are frequent in IVLBCL. • Plasma cfDNA is an alternative tumor DNA source of IVLBCL to detect genetic alterations by comprehensive analyses.
UR - http://www.scopus.com/inward/record.url?scp=85102611544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102611544&partnerID=8YFLogxK
U2 - 10.1182/blood.2020007245
DO - 10.1182/blood.2020007245
M3 - Article
C2 - 33512416
AN - SCOPUS:85102611544
SN - 0006-4971
VL - 137
SP - 1491
EP - 1502
JO - Blood
JF - Blood
IS - 11
ER -